|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,552,000 |
Market
Cap: |
3.00(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.07 - $59.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8 |
Insider 3/6 Months : 8.6 |
|
Guru Rank Number : 538 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
6,156 |
52,347 |
83,197 |
280,515 |
Total Sell Value |
$156,968 |
$1,453,245 |
$3,040,874 |
$12,893,521 |
Total People Sold |
3 |
8 |
10 |
15 |
Total Sell Transactions |
5 |
27 |
33 |
89 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hill Emily Luisa |
Chief Financial Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,800 |
24,122 |
|
- |
|
Schmertzler Michael |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
103,366 |
|
- |
|
Okey Stephanie |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
2,613 |
|
- |
|
Southwell David P |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
3,300 |
|
- |
|
Jacobson Allan Steven |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
5,148 |
|
- |
|
Pauwels Eric |
Chief Business Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
37,280 |
|
- |
|
Graham Dawn |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
27,936 |
|
- |
|
Klein Matthew B. |
Chief Development Officer |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
19,309 |
|
- |
|
Reeve Emma |
Director |
|
2021-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,650 |
4,328 |
|
- |
|
Utter Christine Marie |
SVP, Finance & CAO |
|
2021-01-05 |
4 |
S |
$62.37 |
$19,709 |
D/D |
(316) |
9,488 |
|
41% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-05 |
4 |
S |
$62.37 |
$7,734 |
I/I |
(124) |
1,788 |
|
41% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-05 |
4 |
S |
$62.37 |
$31,310 |
D/D |
(502) |
26,587 |
|
41% |
|
Pauwels Eric |
Chief Business Officer |
|
2021-01-05 |
4 |
S |
$62.37 |
$66,549 |
D/D |
(1,067) |
27,080 |
|
41% |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2021-01-05 |
4 |
S |
$62.37 |
$41,538 |
I/I |
(666) |
11,754 |
|
41% |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2021-01-05 |
4 |
S |
$62.37 |
$87,443 |
D/D |
(1,402) |
54,683 |
|
41% |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2021-01-05 |
4 |
S |
$62.37 |
$17,963 |
D/D |
(288) |
13,322 |
|
41% |
|
Boulding Mark Elliott |
Exec. VP and CLO |
|
2021-01-05 |
4 |
S |
$62.37 |
$48,150 |
D/D |
(772) |
38,952 |
|
41% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-04 |
4 |
AS |
$60.65 |
$36,390 |
I/I |
(600) |
1,912 |
|
-37% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-04 |
4 |
OE |
$10.85 |
$6,510 |
I/I |
600 |
2,512 |
|
- |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-04 |
4 |
AS |
$60.54 |
$6,266,167 |
D/D |
(103,438) |
27,089 |
|
-37% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2021-01-04 |
4 |
OE |
$11.23 |
$2,150,359 |
D/D |
103,438 |
75,214 |
|
- |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2020-12-30 |
4 |
AS |
$61.43 |
$17,641,459 |
D/D |
(285,718) |
56,085 |
|
-37% |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2020-12-30 |
4 |
OE |
$30.86 |
$9,067,681 |
D/D |
285,718 |
172,022 |
|
- |
|
Reeve Emma |
Director |
|
2020-12-15 |
4 |
OE |
$33.02 |
$33,945 |
D/D |
1,028 |
2,678 |
|
- |
|
Reeve Emma |
Director |
|
2020-12-14 |
4 |
AS |
$68.00 |
$134,096 |
D/D |
(1,972) |
1,650 |
|
-29% |
|
566 Records found
|
|
Page 11 of 23 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|